Related Experiment Video
Updated: Mar 19, 2026
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
[Renovascular effects of antiangiogenic drugs]
Gilbert Deray1, Nicolas Janus1, Blandine Aloy1
1Groupe hospitalier Pitié-Salpêtrière, service ICAR, 83, boulevard de l'Hôpital, 75013 Paris, France; Groupe hospitalier Pitié-Salpêtrière, service de néphrologie, 83, boulevard de l'Hôpital, 75013 Paris, France.
Abstract:
During the last decade, inhibitors of the vascular endothelial growth factor (VEGF) were developed for the treatment of cancer. Many anti-VEGF are available but the issue is still the same: to inhibit the effect of the VEGF on their receptors. There are two main classes, depending on the mechanism of action by blocking the binding of the ligand on the receptor (VEGF trap or monoclonal antibody) or by affecting directly the receptor (tyrosine kinase inhibitor [TKI], monoclonal antibody directed against the VEGF receptor). These selective agents are safe. Nevertheless, side effects were described, in particular renal and vascular effects. In this article, we analyze the frequency of these renovascular complications, their clinical aspects and the interest of these indexes as a marker of treatment efficacy.
Insights
Vascular endothelial growth factor (VEGF) inhibitors are used in cancer treatment. This review analyzes the frequency and clinical aspects of renal and vascular side effects from these anti-VEGF therapies.
Area of Science:
- Oncology
- Nephrology
- Cardiovascular Medicine
Background:
- Vascular endothelial growth factor (VEGF) inhibitors are a key class of anti-cancer drugs.
- Available anti-VEGF agents target VEGF signaling through receptor binding inhibition or direct receptor interference.
- Two main classes exist: VEGF traps/monoclonal antibodies and tyrosine kinase inhibitors (TKIs)/anti-VEGF receptor antibodies.
Purpose of the Study:
- To analyze the frequency of renovascular complications associated with anti-VEGF therapies.
- To describe the clinical presentation of these side effects.
- To evaluate the potential of these complications as markers of treatment efficacy.
Main Methods:
- Review of literature on anti-VEGF therapies and their side effects.
- Analysis of reported cases of renal and vascular complications.
- Correlation of complications with treatment response.
Main Results:
- Anti-VEGF agents, while effective, are associated with specific side effects.
- Renovascular complications, including renal and vascular events, are noted.
- The frequency and clinical characteristics of these events require careful monitoring.
Conclusions:
- Renovascular complications are a significant consideration in patients receiving anti-VEGF therapy.
- Understanding these side effects is crucial for patient management.
- Further research may elucidate the role of these complications as predictive markers for treatment outcomes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:24Regulation of Angiogenesis and Blood Supply